文献速递艾滋病与性传播感染

卡博特韦联合利匹韦林长效方案在女性中的真实世界疗效与耐受性:弥合HIV治疗研究中的性别差距

Real-world efficacy and tolerability of CAB+RPV LA in women: addressing the gender gap in HIV treatment research.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

这项单中心回顾性研究分析了270例接受卡博特韦联合利匹韦林长效方案(CAB+RPV LA)的HIV感染者,其中女性42例、男性228例。女性合并症更多(86% vs 49%,P=0.0001)、既往使用≥5种ART方案比例更高(69% vs 29%,P<0.0001)、≥60岁比例更高(31% vs 13%,P=0.003),但病毒学抑制和依从性与男性相当,两组耐受性良好且治疗结局无显著性别差异。

要点

  • 女性合并症比例86% vs 男性49%(P=0.0001),既往≥5种ART方案69% vs 29%(P<0.0001)。
  • 女性≥60岁比例31% vs 男性13%(P=0.003),但病毒学抑制和依从性与男性相当。
  • CAB+RPV LA两组耐受性良好,治疗结局无显著性别差异。

核心结论

  • CAB+RPV LA在具有复杂ART史的女性中有效且耐受性良好,为临床试验中传统上代表性不足的人群提供了可行的长效替代方案。
  • 作者认为这些发现强调了在新型ART方案研究中纳入女性的重要性,以确保公平可及和结局。

研究设计与样本

  • 单中心回顾性研究,纳入270例HIV感染者(女性42例、男性228例),比较接受CAB+RPV LA的女性和男性的病毒学抑制率、依从性和耐受性。

主要发现

  • 女性合并症患病率高于男性(86% vs 49%,P=0.0001)。
  • 女性既往使用≥5种ART方案的比例高于男性(69% vs 29%,P<0.0001)。
  • 女性≥60岁比例为31%,男性为13%(P=0.003)。
  • 尽管合并症和多药治疗率更高,女性的病毒学抑制和依从性与男性相当。
  • CAB+RPV LA在两组中耐受性良好,治疗结局无显著性别差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women, particularly those of advanced age with comorbidities and polypharmacy, are often underrepresented in clinical trials evaluating long-acting (LA) antiretroviral therapy (ART) regimens like cabotegravir and rilpivirine (CAB + RPV LA). This single-center study aims to address this gap by assessing the effectiveness, tolerability, and adherence to CAB + RPV LA, focusing on women who often have complex health profiles. METHODS: In this single-center, retrospective study, we analyzed virologic suppression rates, adherence and tolerability in our cohort of women living with HIV comparing their outcomes to men on the same regimen. RESULTS: A total of 270 individuals (42 women and 228 men) were included. Women had a higher prevalence of comorbidities (86% versus 49%, P = 0.0001), and were more likely to have used ≥5 ART lines (69% versus 29%, P < 0.0001), and 31% were aged ≥60 years compared to 13% of men (P = 0.003). Despite higher rates of comorbidities and polypharmacy, women achieved virologic suppression and adherence levels comparable to men. CAB + RPV LA was well-tolerated in both groups, with no significant gender-based differences in treatment outcomes. CONCLUSION: CAB + RPV LA is effective and well-tolerated in women with complex ART histories, providing a viable long-acting alternative for populations traditionally underrepresented in clinical trials. These findings underscore the importance of including women in studies of novel ART regimens to ensure equitable access and outcomes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Rosas Cancio-Suárez M, Moreno A, Del Campo Terrón S, et al. Real-world efficacy and tolerability of CAB+RPV LA in women: addressing the gender gap in HIV treatment research. J Antimicrob Chemother. 2025. PMID: 39932059. doi:10.1093/jac/dkaf038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。